Nasdaq · Healthcare
Zhengye Biotechnology Holding Ltd (ZYBT)
As-reported financials and recent SEC filings for Zhengye Biotechnology Holding Ltd, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$116.4M
Net income
$-69.8M
Net margin
-60.0%
Diluted EPS
—
ROE
-22.8%
P/E (TTM)
—
Market cap
—
Debt / equity
0.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2024 | FY2024 |
|---|---|---|---|---|
| Revenue | $116.4M | $186.4M | $211.7M | $260.3M |
| Gross profit | $23.9M | $91.3M | $117.5M | $147.9M |
| Operating income | $-70.5M | $16.4M | $45.0M | $65.8M |
| Net income | $-69.8M | $11.3M | $31.5M | $46.7M |
| Diluted EPS | — | $0.25 | $0.69 | $1.02 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
32026-06-25
View on EDGAR →32026-06-25
View on EDGAR →32026-06-25
View on EDGAR →32026-06-25
View on EDGAR →32026-06-25
View on EDGAR →6-K2026-06-04
View on EDGAR →20-F2026-04-28
View on EDGAR →32026-04-24
View on EDGAR →Largest Healthcare peers
Go deeper on ZYBT
Search Zhengye Biotechnology Holding Ltd’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.